An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
Status:
Terminated
Trial end date:
2019-11-20
Target enrollment:
Participant gender:
Summary
This Phase II, multicenter, open-label extension (OLE) study will evaluate the long-term
safety and efficacy of GDC-0853 in participants with systemic lupus erythematosus (SLE) who
have completed Study GA30044 (NCT02908100) up to 48 weeks.